iNANOD AS, an ambitious micro-pharma company revolutionising cancer treatment through targeted and faster drug delivery to solid malignant tumours. iNANOD utilizes nanotechnology to improve drug delivery within cancer chemotherapy, allowing for the targeted and accelerated delivery of active pharmaceutical ingredients. iNANOD founders envisioned a future where nanotechnology, in combination with biotechnology, could transform cancer treatment. iNANOD AS operates on a lean model, strongly supported by a group of experienced advisors, and is dedicated to improving the precision and efficiency of drug delivery to solid tumours. By leveraging market-pull mechanisms of innovation, the company aims to address one of the most pressing challenges in oncology: ensuring that a higher percentage of injected doses reach tumour sites, thereby enhancing treatment efficacy while minimising side effects.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Ullernchausseen 64/66, Oslo,0379,norway
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.inanod.com
- Keywords
- Banarsi Norway.
- HQ
- OSLO
Inanod As Questions
Inanod As's website is http://www.inanod.com
Inanod As's LinkedIn profile is https://no.linkedin.com/company/inanod-as
Inanod As has
6 employees.
View email and phone details for 6
employees at Inanod As.
Inanod As's industry is
Biotechnology Research
Inanod As's top competitors are
Pillar Biosciences Incorporated,
Venturelab Norway,
Amoy Diagnostics,
Remove As,
Domore Diagnostics,
Banarsi Norway,
Effectus Regnskap As,
Dmr-Dahl Market Research As,
Oslo Cancer Cluster,
Global Future As.
Inanod As's categories are Biotechnology Research
Inanod As's founding year is 2016
